Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. - sprookjes - yvandenbroek - TriplyDB

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.

http://www.wikidata.org/entity/Q35779022

about

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer PI3K and AKT: Unfaithful Partners in Cancer Cancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasion Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies The dynamic nature of the kinome Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer Lung cancer cells that survive ionizing radiation show increased integrin α2β1- and EGFR-dependent invasiveness PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.The phosphoinositide 3-kinase pathway and therapy resistance in cancer Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.Genetically engineered mouse models of PI3K signaling in breast cancer.Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance.Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review.A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474 Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Elevated PI3K signaling drives multiple breast cancer subtypes.A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.Will PI3K pathway inhibitors be effective as single agents in patients with cancer?Progress in breast cancer research.

P2860

Q26772969-5188DD03-9765-4ED3-8292-A43A68FD718F Q26781367-F8236746-1B44-49EF-B1E9-897DBA3A0645 Q26796364-202189AF-FFD8-4833-BD78-308A09BE7586 Q26829652-318620A0-81B2-46F5-BA1B-2A5EE6699F13 Q26852588-F107C95C-6B0E-4720-94C4-61925748E07C Q26862550-CCBFEDDE-7DCD-4243-ADF9-BC4D9C7320FE Q27310015-026E5B34-35E1-46B8-9BBC-0B3E5BC05DD3 Q27324467-758A61A8-18F3-4CC1-B63D-EF78332C0F98 Q27679463-0DAA9B66-C1FD-49A3-8A2A-E6DCB106E377 Q27851975-0D723A2F-D99A-4AFF-A1A7-9A470427FFB7 Q27852473-4AE03B4B-7D1D-409B-B9F0-BEB48A88FB89 Q28082811-F6FD3B27-5ECD-4702-9EBF-FC875A2EEA34 Q28084216-87A07B79-9253-41ED-8C2F-920E92A7D248 Q29542169-B640298B-4479-4669-B240-0F08DF0C2343 Q30371561-6776FCC2-2A9A-48C7-9FFD-5E381E1F2A6F Q33601653-485CC537-A2A8-46AB-A5F0-5633C73FA7FC Q33737298-61DA5912-D429-41EB-B831-DFE5482E3A30 Q33776641-E13F9183-D604-436B-95F0-9352AD809AA1 Q33827053-903B1928-6B30-4800-BEF8-F71D5E75DFDB Q33862290-0174DBBD-E71A-44FE-ADF2-5659BEEC201A Q33864932-CBC29A06-D0BF-4788-84EB-C79DE4784419 Q33891230-4C85E34A-3A75-4851-9F8F-7CFF6333C3DC Q34036041-D072D363-FFA8-417A-AAC7-753F89EABB15 Q34036131-27423E7C-9C69-44A6-B214-49ECBD259DF6 Q34205196-ABB39EC4-D1DD-4870-AEA2-A72BA8C14ED8 Q34332175-42355FDF-9A9E-45BF-B7AD-8C7E52349D76 Q34466060-CD89370B-0F68-4E7E-9B70-00CEE8587AD2 Q35077393-4E9504D9-D155-4D45-8FAB-A0628FE878A0 Q35155664-AE203B06-F46E-47BA-8D0E-19EE9D715A8D Q35288044-FBF58607-C6FD-49B7-B1EF-589F8CB8B0D5 Q35374899-1AD58DA9-847B-4EA9-9230-B20226972628 Q35439316-26012C2D-C495-4802-91F8-546225AC5368 Q35535547-642CAC10-F122-4CCC-8F5F-E0965995F63D Q35550099-04C4498B-A686-401F-B002-B2856888B843 Q35624814-F893E8A9-A98A-41F3-9EAA-FC9CCD6FFF8C Q35640263-70B1B0E5-1043-40D9-B65B-9AC77D7D7407 Q35682599-8B90A7CB-6A93-4B99-BBDE-1167E6C9820F Q35746524-6D8A28A0-05AB-468C-9D31-A4B9166EF8E8 Q35764392-22A58917-8795-468E-9435-832DFF44FC21 Q35779144-A3207682-928C-4173-9D95-158B76901ADA

P2860

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.

http://www.wikidata.org/entity/Q35779022

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Feedback upregulation of HER3 ...... mor effect of PI3K inhibitors.

@ast

Feedback upregulation of HER3 ...... mor effect of PI3K inhibitors.

@en

type

label

Feedback upregulation of HER3 ...... mor effect of PI3K inhibitors.

@ast

Feedback upregulation of HER3 ...... mor effect of PI3K inhibitors.

@en

prefLabel

Feedback upregulation of HER3 ...... mor effect of PI3K inhibitors.

@ast

Feedback upregulation of HER3 ...... mor effect of PI3K inhibitors.

@en

P1433

Q35779022-AAE563E0-0BDF-4298-982A-AB53D9EE49CE

P1476

Q35779022-853B0183-0EC8-4855-9129-ACE2E6C30CBC

P2093

Q35779022-45537454-F1AD-4FBE-96C4-88C114D5375A

Q35779022-5C1BE2E2-5226-49B1-A222-1782DF55BBFA

Q35779022-7CC05240-5810-4727-B12D-0ACE689E31F3

Q35779022-7D309868-CAA8-46D6-8F3D-5427A2B4DCD6

Q35779022-E4D80E32-E422-4E15-BED0-288B4E511A1C

P2860

Q35779022-08090D7A-91CF-45DB-A3F4-9626FEF41B27

Q35779022-080BB4A8-6CE2-403E-BF37-9339DB130B8C

Q35779022-0F35AEFA-A97C-4FBB-9983-A0EC3E40DEF5

Q35779022-1C3D6DCD-1399-4839-A563-92DC47C240EF

Q35779022-358766C2-FBC6-4588-848D-BA2738220566

Q35779022-4C42ABDC-6554-40CE-85F3-1B3978FB1692

Q35779022-7D14901E-ADBA-4D91-895F-F7248A7F092C

Q35779022-866B8025-1F93-4670-B579-7AFF8046AAE8

Q35779022-86D4ED7B-80F0-4115-BA08-22FD8F317AE0

Q35779022-8D55BA8B-DE2C-4F7A-A0AF-EC24E1DEE337

P304

Q35779022-DF4FA607-88D2-4923-BA0C-0BE9B0FC97C7

P31

Q35779022-E41606F6-F7C5-4131-8794-9B0DA595FA6D

P356

Q35779022-F2BE0887-DF02-406D-8DA3-B87863E61271

P407

Q35779022-07AC2C5D-AF3C-4892-9FB1-BD067FF134C7

P433

Q35779022-BCAB7B02-F0A9-47E4-9CF7-BEEB76F94B10

P478

Q35779022-7C3FE0C8-1BA5-4D71-B19C-241D8798D3FE

P577

Q35779022-24171E51-F019-4FFA-BAEE-1A19D8F798F3

P5875

Q35779022-1AD18B77-E821-4CFE-813D-C58FF5705B5C

P698

Q35779022-AC5121E1-8726-48D9-BF09-41C53DFDDA03

P921

Q35779022-2C209F9C-C9E2-459B-9945-1E04A1F6C5BF

P932

Q35779022-B29CF80B-9E9C-4353-B7FC-91230EA88921

P356

PNAS.1018001108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Feedback upregulation of HER3 ...... mor effect of PI3K inhibitors.

@en

P2093

Anindita Chakrabarty

http://www.w3.org/2001/XMLSchema#string

Cammie Rinehart

http://www.w3.org/2001/XMLSchema#string

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

María G Kuba

http://www.w3.org/2001/XMLSchema#string

Violeta Sánchez

http://www.w3.org/2001/XMLSchema#string

P2860

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

The PI3K pathway as drug target in human cancer

AKT/PKB signaling: navigating downstream

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

The phosphoinositide 3-kinase pathway

High frequency of mutations of the PIK3CA gene in human cancers

Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor

P304

2718-2723

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1018001108

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50267152

http://www.w3.org/2001/XMLSchema#string

P698

21368164

http://www.w3.org/2001/XMLSchema#string

P921

P932

3286932

http://www.w3.org/2001/XMLSchema#string